Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Table 3 Demographic and clinicopathologic characteristics of patients recruited to the ongoing phase I trial of HER2-pulsed DC1 vaccination in HER2^pos IBC patients with residual disease following neoadjuvant trastuzumab and chemotherapy (NCT02061423)

Subject	Age, y	HLA	Race	Menopausal status	ER	PR	HER2	T + C regimen	Surgery	yp stage
26113-01	67	A2	White	Postmenopausal	+, 30 %	+, 5 %	3+, >90 %	AC/TH	MRM	T1b N2a
26113-02	35	A2	White	Premenopausal	+, 30 %	+, 4 %	2+, FISH +	AC/TH	MRM	T2 N2a
26113-03	45	-	White	Premenopausal	+, 84 %	-, 3 %	3+, >10 %	AC/TH	MRM	Tis N0
26113-04	55	-	White	Postmenopausal	−, 0 %	-, 0 %	3+, >10 %	TC	MRM	T1c N1mi

HER2 human epidermal growth factor receptor 2, DC1 type 1-polarized dendritic cell, IBC invasive breast cancer, HLA human leukocyte antigen (A2 yes/no), ER estrogen receptor, PR progesterone receptor, T + C trastuzumab and chemotherapy, yp post-neoadjuvant pathologic stage, AC/TH Adriamycin/Cyclophosphamide/Taxol/Herceptin, MRM modified radical mastectomy, FISH fluorescence in situ hybridization, TC Taxotere, Cyclophosphamide

ISSN: 1465-542X